ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 239,99
0,17%
Dow Jones
39 850,55
0,74%
DAX
18 869,36
0,78%
Brent Oil
82,675
0,15%
Bitcoin
65 973,26
7,19%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. SAB Biotherapeutics Inc (SABSW)

  7. SAB Biotherapeutics Inc (SABSW) Actualités

SABSW

SAB Biotherapeutics (SABSW)

SAB Biotherapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SABSW
DateHeureSourceTitreSymboleSociété
06/05/202413h15GlobeNewswire Inc.SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
16/04/202413h15GlobeNewswire Inc.SAB Biotherapeutics Provides SAB-142 Trial UpdateNASDAQ:SABSWSAB Biotherapeutics Inc
08/04/202413h15GlobeNewswire Inc.SAB Biotherapeutics to Present at INNODIA Annual MeetingNASDAQ:SABSWSAB Biotherapeutics Inc
04/04/202413h15GlobeNewswire Inc.SAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
29/03/202412h15GlobeNewswire Inc.SAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
25/03/202415h15GlobeNewswire Inc.SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentNASDAQ:SABSWSAB Biotherapeutics Inc
23/02/202414h00GlobeNewswire Inc.SAB Biotherapeutics to Present at the BIO CEO & Investor ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
08/02/202414h00GlobeNewswire Inc.SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
02/02/202413h30GlobeNewswire Inc.SAB Biotherapeutics Announces Executive Leadership ChangeNASDAQ:SABSWSAB Biotherapeutics Inc
23/01/202423h58GlobeNewswire Inc.SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:SABSWSAB Biotherapeutics Inc
02/01/202422h30GlobeNewswire Inc.SAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitNASDAQ:SABSWSAB Biotherapeutics Inc
29/11/202313h30GlobeNewswire Inc.SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
20/11/202313h30GlobeNewswire Inc.SAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
14/11/202313h30GlobeNewswire Inc.SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
14/11/202313h15GlobeNewswire Inc.SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesNASDAQ:SABSWSAB Biotherapeutics Inc
09/11/202313h30GlobeNewswire Inc.SAB Biotherapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
24/10/202313h30GlobeNewswire Inc.SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial OfficerNASDAQ:SABSWSAB Biotherapeutics Inc
19/10/202313h30GlobeNewswire Inc.SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
05/10/202313h30GlobeNewswire Inc.SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
02/10/202313h30GlobeNewswire Inc.SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
21/08/202314h30GlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Q2 2023 Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
21/06/202314h30GlobeNewswire Inc.SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023NASDAQ:SABSWSAB Biotherapeutics Inc
30/05/202314h30GlobeNewswire Inc.SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International ConventionNASDAQ:SABSWSAB Biotherapeutics Inc
19/05/202314h30GlobeNewswire Inc.SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy InnovationsNASDAQ:SABSWSAB Biotherapeutics Inc
16/05/202314h30GlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Q1 2023 Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
12/05/202314h30GlobeNewswire Inc.SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal AntibodiesNASDAQ:SABSWSAB Biotherapeutics Inc
09/05/202314h30GlobeNewswire Inc.SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ PlatformNASDAQ:SABSWSAB Biotherapeutics Inc
04/05/202314h30GlobeNewswire Inc.SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
03/05/202323h00GlobeNewswire Inc.SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11NASDAQ:SABSWSAB Biotherapeutics Inc
26/04/202314h30GlobeNewswire Inc.SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe ComplicationsNASDAQ:SABSWSAB Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SABSW

Dernières Valeurs Consultées

NASDAQ
VEIPX
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés